Advance T cell therapies with non-viral CRISPR

In this application note, GenScript delves into the future of T cell therapies through non-viral strategies, technologies, and methods. Recognizing the constraints of viral-based CRISPR genome editing, the application note highlights the increasing significance of non-viral approaches, particularly in immuno-oncology treatments. These methods utilize CRISPR-Cas9 mRNA/protein and synthetic guide RNA (sgRNA) ribonucleoproteins (RNPs) for direct delivery of CRISPR components, bypassing the need for transcription and translation stages as seen in viral CRISPR delivery. With advancements in DNA synthesis technologies, the generation of long single-stranded DNA and various payload formats become feasible, supporting CRISPR-targeted gene knock-in—ideal for TCR T cell development.